Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | APLNR | P35414 | 5/20 | 0.51 |
| ▸ | BMP1 | P13497 | 1/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 8/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31149207 | 1.00 | L3MBTL1 (0.52) | L3MBTL1APLNRBMP1TAS2R14KCNA5 | |
| SCHEMBL17519246 | 0.91 | APLNR (0.52) | L3MBTL1APLNRBMP1TAS2R14TSHR | |
| SCHEMBL25577924 | 0.88 | APLNR (0.52) | L3MBTL1APLNRTAS2R14KCNA5 | |
| SCHEMBL31149228 | 0.85 | APLNR (0.51) | L3MBTL1APLNRTAS2R14KCNA5 | |
| SCHEMBL20489218 | 0.85 | APLNR (0.51) | L3MBTL1APLNRTAS2R14TSHR | |
| SCHEMBL31149661 | 0.85 | TAS2R14 (0.54) | L3MBTL1APLNRTAS2R14KCNA5 | |
| SCHEMBL31149689 | 0.85 | APLNR (0.51) | L3MBTL1APLNRTAS2R14KCNA5 | |
| SCHEMBL31149695 | 0.84 | APLNR (0.54) | L3MBTL1APLNRTAS2R14 | |
| SCHEMBL31149696 | 0.84 | APLNR (0.54) | L3MBTL1APLNRTAS2R14 | |
| SCHEMBL31525238 | 0.83 | TSHR (0.67) | L3MBTL1APLNRTAS2R14TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841425-A4 | PHENYL-SUBSTITUTED PYRROLIDONES | IRM LLC A DELWARE LTD LIABILIT (BM) | 2009-02-18 | — | — | EP | disclosed |
| US-20080287516-A1 | Phenyl-Substituted Pyrrolidones | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| US-20080287516-A1 | Phenyl-Substituted Pyrrolidones | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
| EP-1841425-A2 | PHENYL-SUBSTITUTED PYRROLIDONES | IRM LLC A Delware Limited Liability Company (BM) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081554-A2 | PHENYL-SUBSTITUTED PYRROLIDONES | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287516-A1 | Phenyl-Substituted Pyrrolidones | MALT1, FKBP5, PREP | L3MBTL1 1325/4885APLNR 4430/4885BMP1 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.